Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2023 | Treatment strategies under investigation for Richter’s transformation

Erin Parry • 7 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia Antibodies

Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly outlines the current landscape of trials exploring the treatment of Richter’s transformation (RT). As RT has been historically difficult to treat with traditional therapies, Dr Parry hopes that clinical trial data looking into alternative therapies will inform the treatment of these patients over the coming years. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Erin Parry

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:36
The genomics of Richter's transformation and evolutionary history of RT from CLL
Erin Parry • 7 Oct 2023
1:17
Diagnosing RT and identifying patients at risk using NGS and molecular cytogenetic analysis
Erin Parry • 7 Oct 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals